chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Joint pain, extreme weakness, confusion and inability to function at normal levels. Temperature of 101 and runny nose that started about 16 - 18 hours after vaccine was administered and peaked around 36 hours post vaccination. Back to normal 48 hours post vaccination.
I had the injection on 12/27/2020, I had the injection. The next morning, my arm was sore, but I didn't think anything of it; I thought it was just normal. It lingered for about 2 days. By 12/29, I didn't notice it anymore. On 1/17/2021, I received the second injection. On 1/18, I noticed the same day-after soreness I had had the first time. It lingered for several weeks. I finally talked to my PCP, Dr., about it on 2/26/2021, and she referred me to my orthopedic doctor, whom I saw on 3/18/2021. When I saw Dr., she also X-rayed my left wrist. Orthopedic Dr. didn't think the pain was related to the vaccine. He thought it was just an overuse injury, so he gave me a cortisone injection in the left wrist. The pain in the wrist went away, but Dr. referred me for an EMG test to be done an another doctor's practice. It was discovered during the EMG that I had a significant pinched nerve in my neck. Dr. then referred me for an MRI, which was done clinic. It was discovered through the MRI that I have spinal stenosis, which has resulted in spinal fusion. I was preparing to undergo surgery for spinal stenosis on 7/6/2021, which I did receive. The pain in my shoulder has now returned, and so has the pain in my left wrist. I plan to see Dr. again as soon as possible.
Pain in the injection site, got the vaccine at 1000am and at the 11hr or 12hr mark I started feeling cold. Woke up at 0130am next day feeling very cold, probably had fever, took Ibuprofen and helped. Also had diarrhea the next day and still felt sensitive and felt cold. At 0900PM I noticed an itchy patch/rash  close to the vaccine injection site about the size of my fist.
Got chills when tired; Got chills when tired; This is a spontaneous report from a contactable consumer (patient). A 58-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EK5730; Expiration date: Mar2021) on 22Dec2020 (11:15) at a single dose on the left arm, with route of administration unspecified, for COVID-19 immunization at the hospital (not at a facility). The patient had no relevant medical history and concomitant medications. On 04Jan2021, the patient got chills when tired; further described as very minor chills in the evening or on and off in the day. The outcome of the events, chills when tired, was recovering. The patient was planning to receive the second dose on 12Jan2021.
Continuous muscle twitching.  Twitching was first noticed at site of the tetanus booster vaccination (right shoulder).  The following day, the muscle twitching moved to the upper right deltoid area, where it twitched consistently for approximately 36 hours.  The twitch is now concentrated in the left deltoid area.  Other non-consistent muscle twitches are occurring randomly throughout the body.  After a revisit to the doctor, I was unable to get a reason as to why the twitching was occurring, and was advised to report as an adverse event.
Patient received Pfizer COVID 19 vaccine on  12/17/2020. Missed appointment for second dose and scheduled self for Moderna first dose on 2/15/21, never telling anyone that he received a first dose of Pfizer. Patient was scheduled and received second dose of Moderna on 3/17/21.
The vial was initially stored in the refrigerator on 08-Jul-2022 and was administered on 09-Aug-2022; No Adverse Event; Administered Moderna COVID-19 Vaccine after 30-day use by date; This spontaneous case was reported by a physician assistant and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administered on 09-Aug-2022) and NO ADVERSE EVENT (No Adverse Event) in a 2-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Aug-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 09-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administered on 09-Aug-2022) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administered on 09-Aug-2022) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Administered Moderna COVID-19 Vaccine after 30-day use by date) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and was administered on 09-Aug-2022).    No concomitant medications were reported.  The reporter mentioned that the vials were initially stored in the fridge on 08-Jul-2022, and vaccine was administered on 09-Aug-2022. The reporter was not aware of any symptoms for any patient after the vaccine was given. Reportedly, the vial didn't undergo any temperature excursions.  No treatment information was provided by the reporter.
This spontaneous report was received from a licensed practical nurse refers to an unspecified number of unspecified patients of unknown age and gender. Medical history, concurrent conditions, and concomitant medications were not reported. On an unknown dates, patients were vaccinated with improperly stored (temperature 47.1 F for 10 minutes, because of data logger) MMR II injection, lot # K024824, expiry date, 02-DEC-2016 (dose, frequency and route of administration not reported). No previous temperature excursion was reported. No adverse effects reported. The outcome of the events was unknown. No product quality complaint (PQC) was involved. GARDASIL 9 and GARDASIL appeared on the product list as temperature stability questions were asked, however, no doses of improperly stored GARDASIL 9 or GARDASIL were administered to patients. No further information was provided. This is one of three reports received from the same reporter. Additional information has been requested.
presented to the emergency room with a 1 week onset of a cough and shortness of breath.  Was seen by his primary care physician initially, however  presented to the emergency room due to worsening symptoms.    He has been afebrile denied any chills or sweats.  On presentation he was hypoxic and saturating at 88% on room air.  COVID-19 PCR was positive. He received his MODERNA vaccine x2 in April. He had an elevated interleukin 6 of 21.1.  A chest x-ray done on admission revealed mild diffuse bilateral interstitial edema.  proBNP 12,900  WBC 9.58  A chest x-ray revealed mild diffuse bilateral interstitial edema  Tested positive on 12/06/2021
12 days post vaccination developed fever, truncal rash, axillary lymphadenopathy, posterior cervical lymphadenopathy fatigue muscle pain.
Per provider her left arm (Pneumo vac) and right arm (Flu vac) swelled up and developed a rash.
CHILLS; FEVER; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced chills, and fever. The action taken with covid-19 vaccine was not applicable. The outcome of the fever and chills was not reported. This report was non-serious.
INJECTION SITE PURPLE; SWOLLEN ARM; REDNESS ON ARM; ITCHY ON INJECTION SITE; VOMITING BLOOD; DIZZY; UNABLE TO EAT; VOMITING; PAIN IN ARM/ UNABLE TO LIFT ARM ABOVE HEAD; SORENESS AT INJECTION SITE; TIRED; FEVER; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number: unknown) dose was not reported, 1 total administered on 05-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 05-APR-2021, the patient felt dizzy, was tired, had a fever and soreness at injection site. The patient could not lift her arm above head without being in pain. She was unable to eat anything the entire day. The patient attempted to eat some soup but, threw it up. On 07-APR-2021 at 03:00, the patient woke up and drank some water but within ten minutes she threw that up along with blood and later her temperature was 104.8 (unit unspecified). On 07-APR-2021 afternoon, the patient was not able to eat anything but she drank some gatorade. On 08-APR-2021 afternoon, the patient's fever broke. On 09-APR-2021, the patient was able to go to work; however the patient's arms still hurt and was red and swollen. The patient's injection site began to itch and it continued up to that weekend. On 11-APR-2021, the injection arm was swollen for about an hour. On 13-APR-2021, the patient felt fine but her injection site was purple. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting blood, dizzy, unable to eat, redness on arm, itchy on injection site, vomiting, pain in arm/ unable to lift arm above head, soreness at injection site, and tired on APR-2021, swollen arm on 11-APR-2021, and fever on 08-APR-2021, and had not recovered from injection site purple. This report was serious (Other Medically Important Condition).; Sender's Comments: V0; 20210425153-covid-19 vaccine ad26.cov2. s- vomiting blood. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.
2 days past vaccine: developed localized skin rash with centralized cluster of vesicles around 3x4 cm = erythematous warm area 14x16cm over right upper lateral aspect of arm.
tested positive; tested positive; This is a spontaneous report from a contactable consumer.  A 72-years-old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm on 04Feb2021 (Batch/Lot Number: EL9265) as SINGLE DOSE, dose 2 via an unspecified route of administration, administered in Arm on 25Feb2021 (Batch/Lot Number: EN6202) as SINGLE DOSE for covid-19 immunisation.  Medical history included blood pressure measurement from an unknown date and unknown if ongoing. Concomitant medication(s) included aspirin [acetylsalicylic acid] (ASPIRIN [ACETYLSALICYLIC ACID]) taken for an unspecified indication, start and stop date were not reported. The patient tested positive (vaccination failure) on 01Apr2021 with outcome of unknown. The action taken in response to the event(s) for bnt162b2 was not applicable.  Follow-up attempts are completed. No further information is expected.
Itchy bumpy rash welts on chest stomach abdomen; Itchy bumpy rash welts on chest stomach abdomen; Itchy bumpy rash welts on chest stomach abdomen; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date unknown), via an unspecified route of administration administered in arm left on 30Jan2021 12:45 as 1st dose, single for covid-19 immunisation. Medical history included asthma. Concomitant medications included topiramate and; venlafaxine (VENLAFAXINE) - both taken for unspecified indications, start and stop dates were not reported. The patient did not have covid prior vaccination. The patient experienced itchy bumpy rash welts on chest stomach abdomen on 05Feb2021. No treatment was received for the adverse events. The patient had not recovered from the adverse events at the time of the report. The patient was vaccinated with the 2nd dose of BNT162B2 on 20Feb2021 09:45 administered in the left arm. The patient has not been tested for covid post-vaccination.  Follow-up attempts are completed; information about the lot/batch number cannot be obtained. No further information is expected.
This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's pertinent medical history and drug reactions or allergies were not reported. On 27-JUN-2016, the patient was vaccinated with improperly stored doses of GARDASIL 9 (lot # L024993 and expiration date 17-OCT-2017 (strength, dose number, anatomical location and route of administration were not reported)). Concomitant therapies were not reported. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Muscle aches, arm soreness, shoulder tightness, lightheadedness (better), decreased appetite. patient taking tylenol and aleve to help alleviate symptoms.  Symptoms began 6/23/2021 at 6PM. lightheadedness recovered.
REDNESS, ERYTHEMA, AND SWELLING TO RIGHT THIGH. DIAGNOSED WITH ACUTE CELLULITIS RIGHT THIGH.  PATIENT TO START IBUPROFEN ON 10/24/2008 AND IF NO IMPROVEMENT BY SUNDAY(10/26/2008) START AUGMENTIN.
PT STATED FELT NUMBNESS/TINGLING STARTING IN FINGERTIPS & HAND AND PROGRESSED UP HER ARM TO SHOULDER. SHE WAS GIVEN BENADRYL TO HELP ABATE REACTION. SHE STATED FOR OBSERVATION FOR 30 MINUTES POST-VACCINATION. THE NUMBNESS HADN'T STOPPED WHEN SHE LEFT BUT SHE DID STATE IF THE REACTION CONTINUED INTO TOMORROW SHE WOULD GO TO SEE A DOCTOR.
Information has been received from a 25 year old female medical assistant who on an unknown date, was vaccinated with the first dose of GARDASIL vaccine (yeast). On unreported date, the patient was vaccinated with the second dose of GARDASIL vaccine (yeast). The medical assistant reported that after the first dose she felt a little bit of pain at the injection site, and after 3 days it was itchy. She also, reported that she didn't have a reaction to the second dose. At the time of the report the patient had recovered. Additional information has been requested.
Patient experienced Vomiting.. Pain and swollen arm to the touch.  Also severe fatigue.
See attached page 1 and 2 on ZLB letterhead. SXS severe cramping bilaterally upper forearms and lower thigh upper calves. Has refused to seek HCP evaluation at this time.
Slept for 9 hours woke up with a big red sore on injection site fever of 104 and was letting out one big scream without hardly breathing in between screams he was givin Lortab and was in the ER for 5 hours to be checked on before it was ok to take him home.
I had an enlarged lymph node located on top of my clavicle bone that moved independently; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP). The reporter is the patient.  A 28 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 03Feb2021 09:00 (Lot number: EL 3247) at the age of 28 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 16Feb2021, outcome "not recovered", described as "I had an enlarged lymph node located on top of my clavicle bone that moved independently". The event "i had an enlarged lymph node located on top of my clavicle bone that moved independently" was evaluated at the physician office visit.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19; and since the vaccination, has not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received birth control within 2 weeks of vaccination. It was also reported that patient visited her primary care physician on Monday 22Feb2021 to make sure she was ok receiving her second vaccine on 24Feb2021. Physician said patient was safe to receive it and that they would self-monitor the lymph node for 4-6 weeks after the second vaccine. Patient also reported that physician stated it felt to be as big as 1 millimeter.  No follow-up attempts are possible. No further information is expected.
It is almost 6 months now from her first dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (It is almost 6 months now from her first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In December 2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (It is almost 6 months now from her first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (It is almost 6 months now from her first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment was reported.  Action taken with mRNA-1273 in response to the event was not applicable.
Warm  and red on the injection site; Rash on the injection site; Warm  and red on the injection site; Slight soreness on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warm  and red on the injection site), VACCINATION SITE PAIN (Slight soreness on the injection site), VACCINATION SITE RASH (Rash on the injection site) and VACCINATION SITE ERYTHEMA (Warm and red on the injection site) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     Concomitant products included WARFARIN and SIMVASTATIN.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced VACCINATION SITE PAIN (Slight soreness on the injection site). On 19-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Warm  and red on the injection site), VACCINATION SITE RASH (Rash on the injection site) and VACCINATION SITE ERYTHEMA (Warm  and red on the injection site). At the time of the report, VACCINATION SITE WARMTH (Warm  and red on the injection site), VACCINATION SITE PAIN (Slight soreness on the injection site), VACCINATION SITE RASH (Rash on the injection site) and VACCINATION SITE ERYTHEMA (Warm  and red on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       treatment information not provided   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Reporter email address was added
This spontaneous report was received from a registered nurse and refers to a 12 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 18-JUL-2017, the patient was vaccinated with an improperly stored VARIVAX at a dose of 0.5 (units not specified) from lot # N012132 with expiry date: 17-APR-2019 (dose number, route, anatomical location and site of administration were not reported) for prophylaxis. Concomitant medications included a properly stored sterile diluent (manufacturer unknown). The administered dose of vaccine was stored in the temperature between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 20 hours and in the temperature between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 6 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No additional information was provided. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1707USA004945.
no additional AEs; CMA called to report TE from 2/22/23 and states that 4 doses of PROQUAD were administered prior to stability evaluation on 3/2/23; This non-valid spontaneous report was received from a medical assistant referring to an unknown number of patients of unknown ages and genders. Information about the patients' pertinent medical history, concurrent conditions, concomitant medications and drug reactions/allergies was not provided.  On 22-FEB-2023, the patients were vaccinated with improperly stored doses of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (once, 0.5 mL, lot number: W034977 has been verified to be a non-valid lot number, expiration date: 05-MAY-2024, routes of administration and anatomical locations were not provided) for prophylaxis (product storage error).   On 22-FEB-2023, the vaccines experienced a temperature excursion from -14 to -10 (-13.6) degrees Celsius for 21 minutes. It was stated that 4 doses of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) were administered prior to stabilty evaluation. There were no reported previous temperature excursions. No additional adverse events (AEs) or product quality complaints (PQC) were reported (no adverse event). No further information was provided. The outcome of product storage error and no adverse event was unknown.   This case is non-valid due to an unknown number of patients and lack of patients' identifiers.  Follow-up information has been received from a medical assistant on 16-MAR-2023  The patient was a 29-months male (2 years-old), who had a birth weight 7lbs 14 oz.  On 28-FEB-2023, the patient was vaccinated with improper storage vaccine Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (lot # W028568 has been verified to be valid lot, expiration date 06-MAR-2024), subcutaneously in left thigh (product storage error). The outcome was informed as recovered.  The reporter considered the event to be attributable to the suspect vaccine, and important medical event (medically significant).   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2303USA000873:Master case US-009507513-2303USA006896: US-009507513-2303USA006895:
Woke up day after shot feeling sick and woosey.  Headache that continued to get worse all day.  Felt kind of out of it.  Light headed.  Tired. I was hot  so hot. Husband said I had fever and was a bit delusional but I don't remember for sure.  I just know I felt awful.  He wanted to take me to doctor or hospital but I declined and wanted to sleep it off.   The next day I feel fine.
rash to L forearm and R forearm. rash appears streaked, student stating jacket lining causing area feel itchy area washed cool water and soap itching stopped parent contacted.
Narrative: Patient received two doses of covid vaccine. patient has PMH of metastatic prostate cancer and died on hospice care. No other concerns of death reported related to vaccine given. Reporting per Regulatory Authority instruction.
After receiving vaccinations, patient passed out for a few seconds from sitting at a table.  His head touched the floor.